Cargando…

Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer

SIMPLE SUMMARY: Oligometastatic prostate cancer has classically been defined as a small volume of prostate cancer spread as defined by imaging using CT, MRI, and bone scans. With development and integration of more sensitive functional imaging including PSMA-PET imaging more oligometastatic disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galgano, Samuel J., McDonald, Andrew M., West, Janelle T., Rais-Bahrami, Soroush
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313368/ https://www.ncbi.nlm.nih.gov/pubmed/35884362 http://dx.doi.org/10.3390/cancers14143302

Ejemplares similares

Role of molecular imaging in the detection of localized prostate cancer
por: Galgano, Samuel J., et al.
Publicado: (2022)

Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET
por: Sabbagh, Ali, et al.
Publicado: (2022)

Imaging for the Initial Staging and Post-Treatment Surveillance of Penile Squamous Cell Carcinoma
por: Galgano, Samuel J., et al.
Publicado: (2022)

Contemporary Review of Multimodality Imaging of the Prostate Gland
por: Calderone, Carli E., et al.
Publicado: (2023)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer
por: Mohan, Riche, et al.
Publicado: (2023)

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
por: Alberto, Matthew, et al.
Publicado: (2022)

Lymph node imaging in initial staging of prostate cancer: An overview and update
por: Zarzour, Jessica G, et al.
Publicado: (2017)

The Role of Imaging in Bladder Cancer Diagnosis and Staging
por: Galgano, Samuel J., et al.
Publicado: (2020)

Metastatic prostate cancer to an ischiorectal fossa lymph node identified on multiparametric magnetic resonance imaging
por: Fang, Andrew M., et al.
Publicado: (2020)

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
por: Kalinauskaite, Goda, et al.
Publicado: (2020)

The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
por: Erdoğan, Mehmet, et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

PSMA-PET in the early stages of prostate cancer
por: Barbosa, Felipe de Galiza
Publicado: (2023)

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT
por: Ross, M. I., et al.
Publicado: (2020)

Imaging as a Personalized Biomarker for Prostate Cancer Risk Stratification
por: Gennaro, Kyle H., et al.
Publicado: (2018)

Correction to: Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT
por: Ross, M. I., et al.
Publicado: (2020)

Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine
por: Dulaney, Caleb R., et al.
Publicado: (2016)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
por: Combes, Alexander D., et al.
Publicado: (2022)

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
por: Cereser, Lorenzo, et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
por: Deijen, Charlotte L., et al.
Publicado: (2021)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

The added value of PSMA PET/MR radiomics for prostate cancer staging
por: Solari, Esteban Lucas, et al.
Publicado: (2021)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
por: Vetrone, Luigia, et al.
Publicado: (2023)

Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy
por: Gawish, Ahmed, et al.
Publicado: (2022)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

Multiparametric MRI in the PSA Screening Era
por: George, Arvin K., et al.
Publicado: (2014)

Personalized prostate cancer care
por: Rais-Bahrami, Soroush, et al.
Publicado: (2018)

Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer
por: Galgano, Samuel J., et al.
Publicado: (2018)

PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review
por: Petersen, Lars J., et al.
Publicado: (2020)

Risk of metastatic disease using [(18)F]PSMA-1007 PET/CT for primary prostate cancer staging
por: Chikatamarla, Venkata Avinash, et al.
Publicado: (2021)

Feasibility of Dose Escalating [(18)F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer
por: McDonald, Andrew M., et al.
Publicado: (2019)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
por: Leung, Kevin H., et al.
Publicado: (2022)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Accuracy of (68)Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer
por: Barbosa, Álan Roger Gomes, et al.
Publicado: (2022)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer
por: Kichloo, Asim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hgdtbtvfvfpb7pbn0emrv1cu52